Medtronic reports earnings up 40.74 percent: Medtronic stock sits 7.79 percent below its high

Published on 10/27/2026 at 16:32 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Adjusted EPS reached USD 1.45 versus USD 1.39 consensus. Medtronic stock costs EUR 84.37 October 27, 2026, 0.06 percent above Xetra close.

Earnings and reporting date

Medtronic reported diluted earnings per share of USD 1.14 for fiscal first quarter 2027, up 40.74 percent year over year.
Adjusted earnings per share reached USD 1.45 versus USD 1.39 consensus for fiscal first quarter 2027.
Medtronic stock costs EUR 84.37 at Lang & Schwarz on October 27, 2026 at 4:16 p.m. CEST, 0.06 percent above the Xetra close of October 26, 2026.
Medtronic is estimated to report fiscal second-quarter 2027 results on November 17, 2026.

Medtronic plc, IE00BTN1Y115, Illustration mit AI erstellt.

Medtronic reported diluted GAAP earnings per share of USD 1.14 for fiscal first quarter 2027, up from USD 0.81 a year earlier, a 40.74 percent increase. The figures were reported for the quarter ended July 31, 2026, and are carried by BuyMeWhiskey. Medtronic stock was trading at EUR 84.37 at Lang & Schwarz on October 27, 2026 at 4:16 p.m. CEST, up 0.06 percent versus the Xetra close of October 26, 2026 at EUR 84.32.

Adjusted earnings beat estimates

Adjusted earnings per share reached USD 1.45 in fiscal first quarter 2027, compared with a consensus estimate of USD 1.39. That 4.32 percent beat accompanied revenue of USD 9.76 billion, which was 13.70 percent higher than a year earlier, according to MarketBeat.

Stock stays below its yearly high

The Lang & Schwarz price stood 7.79 percent below Medtronic's 52-week high of EUR 91.50. Its 52-week low was EUR 62.86, while the same-day Xetra quote was EUR 84.44 at 5:07 p.m. CEST, with a volume of 247 shares in the quoted market.

Valuation and next date

Medtronic had a market capitalization of USD 120.2 billion and a price-to-earnings ratio of 23.14 on October 27, 2026. Its trailing dividend yield was 3.00 percent. The next fiscal second-quarter 2027 report is estimated for November 17, 2026, before the US market opens, according to MarketBeat.

Comparison with peers

Medtronic: 0.88 percent intraday gain in USD terms, price-to-earnings ratio 23.35, market capitalization USD 108.0 billion. Abbott Laboratories (NYSE, USD): down 1.63 percent, price-to-earnings ratio 38.18, market capitalization USD 178.5 billion. Johnson & Johnson (NYSE, USD): up 0.72 percent, price-to-earnings ratio 40.67, market capitalization USD 645.7 billion.

Investors weigh growth against valuation

The earnings comparison gives Medtronic a stronger operating reference than its modest euro move on October 27, 2026. The key watchpoint is whether the next report can sustain the 13.70 percent revenue growth recorded in fiscal first quarter 2027 while the stock remains below its EUR 91.50 yearly high. The stock was trading at EUR 84.37 at Lang & Schwarz on October 27, 2026 at 4:16 p.m. CEST, 0.06 percent above the Xetra close of October 26, 2026 at EUR 84.32. The further course of trading is shown by the continuously updated real-time quote of Medtronic stock.